Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
															Search

		Submit


Tuberculosis (TB)


Facebook
        Twitter
        LinkedIn
        Syndicate





TB-Related Articles										Related Pages
										Journal Articles Published by Division of TB Elimination (DTBE) Authors
2015 DTBE Publications
Agaya J, Nnadi CD, Odhiambo J, Obonyo C, Obiero V, Lipke V, Okeyo E, Cain K, Oeltmann JE. Tuberculosis and latent tuberculosis infection among health care workers in Kisumu, Kenya.external icon Trop Med Int Health. 2015 Dec;20(12):1797-804. doi: 10.1111/tmi.12601. PMID: 26376085.
Baker BJ, Holtmon PD. Additional benefits of GeneXpert MTB/RIF assay for the evaluation of pulmonary tuberculosis among inpatients. Clin Infect Dis.external icon 2015 Apr 15;60(8):1287-8. doi: 10.1093/cid/civ006. Epub 2015 Jan 13.
Balaban V, Marks SM, Etkind SC, Katz DJ, Higashi J, Flood J, Cronin A, Ho CS, Khan A, Chorba T. Tuberculosis Elimination Efforts in the United States in the Era of Insurance Expansion and the Affordable Care Act.external icon Public Health Rep. 2015 Jul-Aug;130(4):349-54. PMID: 26345625.Year202120202019201820172016201520142013Baldwin PR, Reeves AZ, Powell KR, Napier RJ, Swimm AI, Sun A, Giesler K, Bommarius B, Shinnick TM, Snyder JP, Liotta DC, Kalman D. Monocarbonyl analogs of curcumin inhibit growth of antibiotic sensitive and resistant strains of Mycobacterium tuberculosis.external icon Eur J Med Chem. 2015 Mar 6;92:693-9. doi: 10.1016/j.ejmech.2015.01.020. Epub 2015 Jan 10. PMID: 25618016.
Bemis K, Thornton A, Rodriguez-Lainz A, Lowenthal P, Escobedo M, Sosa LE, Tibbs A, Sharnprapai S, Moser KS, Cochran J, Lobato MN. Civil Surgeon Tuberculosis Evaluations for Foreign-Born Persons Seeking Permanent U.S. Residence. J Immigr Minor Health.external icon 2015 Feb 13. [Epub ahead of print] PMID: 25672993.
Binepal  P, Agarwal P, Kaur N, Singh B, Bhagat V, Verma RP, Satyanarayana S, Oeltmann JE, Moonan PK. Screening difficult-to-reach populations for tuberculosis using a mobile medical unit, Punjab India. Public Health Action. 2015;5(4):177-79.
Bliven-Sizemore EE, Sterling TR, Shang N, Benator D, Schwartzman K, Reves R, Drobeniuc J, Bock N, Villarino ME; TB Trials Consortium. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI.external icon Int J Tuberc Lung Dis. 2015 Sep;19(9):1039-44. doi: 10.5588/ijtld.14.0829. PMID: 26260821.
Borgdorff MW, Cain KP, DeCock KM. The molecular epidemiology of tuberculosis in settings with a high HIV prevalence: implications for control.external icon J Infect Dis. 2015 Jan 1;211(1):8-9. doi: 10.1093/infdis/jiu404. Epub 2014 Jul 22. PMID: 25053740.
Bulage L, Imoko J, Kirenga B, Lo T, Byabajungu T, Musisi K, Joloba M, Bloss E. Quality of sputum submitted for drug susceptibility testing at the National Tuberculosis Reference Laboratory Uganda, July-October 2013. Journal of Tuberculosis Research. 2015 Sep; 3(3):97-106.
Cain KP, Marano N, Kamene M, Sitienei J, Mukherjee S, Galev A, Burton J, Nasibov O, Kioko J, De Cock KM. The Movement of Multidrug-Resistant Tuberculosis across Borders in East Africa Needs a Regional and Global Solution.external icon PLoS Med. 2015 Feb 24;12(2):e1001791. doi: 10.1371/journal.pmed.1001791. eCollection 2015 Feb.  PMID: 25710472.
Cain KP, Shah NS. (Not) measuring in the dark.external icon Int J Tuberc Lung Dis. 2015 Nov;19(11):1270. doi: 10.5588/ijtld.15.0782. PMID: 26467576.
Cavanaugh J, Viney K, Kienene T, Harley D, Kelly PM, Sleigh A, O’Connor J, Mase S. Effect of diabetes on tuberculosis presentation and outcomes in Kiribati. Trop Med Int Health.external icon 2015 May;20(5):643-649. doi: 10.1111/tmi.12468. Epub 2015 Feb 18.
Cavanaugh JS, Kurbatova E, Alami NN, Mangan J, Sultana Z, Ahmed S, Begum V, Sultana S, Daru P, Ershova J, Golubkov A, Banu S, Heffelfinger JD. Evaluation of Community-Based Treatment for Drug-Resistant Tuberculosis in Bangladesh.external icon Trop Med Int Health. 2015 Oct 22. doi: 10.1111/tmi.12625. [Epub ahead of print]. PMID: 26489698.
CDC (Scott C, Kirking HL, Jeffries C, Price SF, Pratt R) Tuberculosis Trends — United States, 2014. *MMWR* 2015 March 20; **64(10);265-269.**
CDC (Scott C, Kirking HL, Jeffries C, Price SF, Pratt R) World TB Day — March 24, 2015. *MMWR* Morb Mortal Wkly Rep. 2015 Mar 20;64(10):265-9.
Cegielski JP, Chen MP, Tupasi TE, Leimane V, Volchenkov GV. Global Preserving Effective TB Treatment Study Investigators. Reply to Soman et al, Alffenaar et al, Metcalfe et al, and Raoult.external icon Clin Infect Dis. 2015 Mar 15;60(6):971-3. doi: 10.1093/cid/ciu1150. Epub 2014 Dec 19. PMID: 25527654.
Cegielski JP, Kurbatova E, van der Walt M, Brand J, Ershova J, Tupasi T, Campos Caoili J, Dalton T, Contreras C, Yagui M, Bayona J, Kvasnovsky C, Leimane V, Kuksa L, Chen MP, Via LE, Hwang SH, Wolfgang M, Volchenkov GV, Somova T, Smith SE, Akksilp S, Wattanaamornkiet W, Kim HJ, Kim CK, Kazennyy BY, Khorosheva T, Kliiman K, Viiklepp P, Jou R, Huang AS, Vasilyeva IA, Demikhova OV; Global PETTS Investigators. Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment, Initial and Acquired Second-Line Drug Resistance.external icon Clin Infect Dis. 2015 Oct 27. pii: civ910. [Epub ahead of print]. PMID: 26508515
Cegielski P, Vernon A. Tuberculosis and vitamin D: what’s the rest of the story? Lancet Infect Dis.external icon 2015 May;15(5):489-90. doi: 10.1016/S1473-3099(15)70163-5. Epub 2015 Apr 8.
Chapman KN, Pevzner E, Mangan JM, Breese P, Lamunu D, Shrestha-Kuwahara R, Nakibali JG, Goldberg SV. Evaluation of the informed consent process of a multicenter tuberculosis treatment trial. *AJOB Empirical Bioethics*2015;6:31–43. DOI:10.1080/23294515.2015.1015184.
Chorba, T. A master medalist, a President, tuberculosis and a Congress: contributions more lasting than bronze. Emerging Infectious Diseases 2015;21:553-4.
Click, ES. How is TB transmitted?external icon [Short communication] Chest 2015 April;147(4):e158. DOI:10.1378/chest.14-3111. PubMed ID: 25846543.
Coscolla M, Barry PM, Oeltmann JE, Koshinsky H, Shaw T, Cilnis M, Posey J, Rose J, Weber T, Fofanov VY, Gagneux S, Kato-Maeda M, Metcalfe JZ. Genomic epidemiology of multidrug-resistant Mycobacterium tuberculosis during transcontinental spread. J Infect Dis.external icon 2015 Jul 15;212(2):302-10. doi: 10.1093/infdis/jiv025. Epub 2015 Jan 18.
Davidow AL, Katz D, Ghosh S, Blumberg H, Tamhane A, Sevilla A, Reves R. Tuberculosis Epidemiologic Studies Consortium. Preventing Infectious Pulmonary Tuberculosis Among Foreign-Born Residents of the United States.external icon Am J Public Health. 2015 Sep;105(9):e81-8. doi: 10.2105/AJPH.2015.302662. Epub 2015 Jul 16.
Denkinger CM, Kik SV, Cirillo DM, Casenghi M, Shinnick T, Weyer K, Gilpin C, Boehme CC, Schito M, Kimerling M, Pai M. Defining the needs for next generation assays for tuberculosis. J Infect Dis.external icon 2015 Apr 1;211 Suppl 2:S29-38. doi: 10.1093/infdis/jiu821.
Deshmukh RD, Dhande DJ, Sachdeva KS, Sreenivas A, Kumar AM, Satyanarayana S, Parmar M, Moonan PK, Lo TQ. Patient and Provider Reported Reasons for Lost to Follow Up in MDRTB Treatment: A Qualitative Study from a Drug Resistant TB Centre in India.external icon PLoS One. 2015 Aug 24;10(8):e0135802. doi: 10.1371/journal.pone.0135802. eCollection 2015. PMID: 26301748.
Dorman SE, Savic RM, Goldberg S, Stout JE, Schluger N, Muzanyi G, Johnson JL, Nahid P, Hecker EJ, Heilig CM, Bozeman L, Feng PJ, Moro RN, MacKenzie W, Dooley KE, Nuermberger EL, Vernon A, Weiner M; Tuberculosis Trials Consortium. Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med.external icon 2015 Feb 1;191(3):333-43. doi: 10.1164/rccm.201410-1843OC.
Ershova JV, Volchenkov GV, Kaminski DA, Somova TR, Kuznetsova TA, Kaunetis NV, Cegielski JP, Kurbatova EV. Epidemiology of Primary Multidrug-Resistant Tuberculosis, Vladimir Region, Russia.external icon Emerg Infect Dis. 2015 Nov;21(11):2048-51. doi: 10.3201/eid2111.150813. PMID: 26488585.
France AM, Grant J, Kammerer JS, Navin TR. A Field-Validated Approach Using Surveillance and Genotyping Data to Estimate Tuberculosis Attributable to Recent Transmission in the United States.external icon Am J Epidemiol. 2015 Nov 1;182(9):799-807. Epub 2015 Oct 13. PMID: 26464470.
Gallivan M, Shah N, Flood J. Epidemiology of human Mycobacterium bovis disease, California, USA, 2003-2011.external icon Emerg Infect Dis. 2015 Mar;21(3):435-43. doi: 10.3201/eid2103.141539. PMID: 25693687.
Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, Den Boon S, Borroto Gutierrez SM, Bruchfeld J, Burhan E, Cavalcante S, Cedillos R, Chaisson R, Chee CB, Chesire L, Corbett E, Dara M, Denholm J, de Vries G, Falzon D, Ford N, Gale-Rowe M, Gilpin C, Girardi E, Go UY, Govindasamy D, Grant AD, Grzemska M, Harris R, Horsburgh CR Jr, Ismayilov A, Jaramillo E, Kik S, Kranzer K, Lienhardt C, LoBue P, Lönnroth K, Marks G, Menzies D, Migliori GB, Mosca D, Mukadi YD, Mwinga A, Nelson L, Nishikiori N, Oordt-Speets A, Rangaka MX, Reis A, Rotz L, Sandgren A, Sañé Schepisi M, Schünemann HJ, Sharma SK, Sotgiu G, Stagg HR, Sterling TR, Tayeb T, Uplekar M, van der Werf MJ, Vandevelde W, van Kessel F, Van’t Hoog A, Varma JK, Vezhnina N, Voniatis C, Vonk Noordegraaf-Schouten M, Weil D, Weyer K, Wilkinson RJ, Yoshiyama T, Zellweger JP, Raviglione M. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.external icon Eur Respir J. 2015 Sep 24. pii: ERJ-01245-2015. doi: 10.1183/13993003.01245-2015. [Epub ahead of print].  PMID: 26405286.
Grosset J, Vernon A. A reader’s guide to the bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.external icon Am J Respir Crit Care Med. 2015 Apr 15;191(8):871-3. doi: 10.1164/rccm.201502-0367ED. PMID:25876201
Haddad MB, Mitruka K, Oeltmann JE, Johns EB, Navin TR. Characteristics of Tuberculosis Cases that Started Outbreaks in the United States, 2002-2011. Emerg Infect Dis.external icon 2015 Mar;21(3):508-10. doi: 10.3201/eid2103.141475.
Hirsch-Moverman Y, Cronin WA, Chen B, Moran JA, Munk E, Reichler MR; Tuberculosis Epidemiological Studies Consortium Task Order 2 Team. HIV counseling and testing in tuberculosis contact investigations in the United States and Canada.external icon Int J Tuberc Lung Dis. 2015 Aug;19(8):943-53. doi: 10.5588/ijtld.14.0642. PMID: 26162361.
Hirsch-Moverman Y, Shrestha-Kuwahara R, Bethel J, Blumberg HM, Venkatappa TK, Horsburgh CR, Colson PW. Tuberculosis Epidemiologic Studies Consortium (TBESC). Latent tuberculous infection in the United States and Canada: who completes treatment and why? Int J Tuberc Lung Dis.external icon 2015 Jan;19(1):31-8. doi: 10.5588/ijtld.14.0373.
Howley MM, Painter JA, Katz DJ, Graviss EA, Reves R, Beavers SF, Garrett DO; Tuberculosis Epidemiologic Studies Consortium. Evaluation of QuantiFERON-TB gold in-tube and tuberculin skin tests among immigrant children being screened for latent tuberculosis infection.external icon Pediatr Infect Dis J. 2015 Jan;34(1):35-9. doi: 10.1097/INF.0000000000000494. PMID: 25093974.
Interrante JD, Haddad MB, Kim L, Gandhi NR.  Exogenous Reinfection as a Cause of Late Recurrent Tuberculosis in the United States. Ann Am Thorac Soc.external icon 2015 Nov;12(11):1619-26. doi: 10.1513/AnnalsATS.201507-429OC. PMID: 26325356.
Interrante JD, Haddad MB, Kim L, Gandhi NR. Reply: Missing Stowaways and Lack of Expected Concurrent Infections.external icon Ann Am Thorac Soc. 2015 Dec;12(12):1898-9. doi: 10.1513/AnnalsATS.201509-651LE. No abstract available. PMID: 26653200.
Jackson DA, Mailer K, Porter KA, Niemeier RT, Fearey DA, Pope L, Lambert LA, Mitruka K, de Perio MA. Challenges in assessing transmission of Mycobacterium tuberculosis in long-term-care facilities.external icon Am J Infect Control. 2015 May 5. pii: S0196-6553(15)00223-0. doi: 10.1016/j.ajic.2015.03.035. [Epub ahead of print] PMID: 25952618.
Jackson-Morris A, Fujiwara PI, Pevzner E. Clearing the smoke around the TB-HIV syndemic: smoking as a critical issue for TB and HIV treatment and care.external icon Int J Tuberc Lung Dis. 2015 Sep;19(9):1003-6. doi: 10.5588/ijtld.14.0813. PMID: 26260816.
*Jayakumar A, Vittinghoff E, Segal MR, MacKenzie WR, Johnson JL, Gitta P, Saukkonen J, Anderson J, Weiner M, Engle M, Yoon C, Kato-Maeda M, Nahid P;***Tuberculosis***Trials Consortium.*Serum biomarkers of treatment response within a randomized clinical trial for pulmonary tuberculosis. Tuberculosis (Edinb).external icon 2015 Jul;95(4):415-20. doi: 10.1016/j.tube.2015.04.011. Epub 2015 May 9.
Khaparde K, Jethani P, Dewan PK, Nair SA, Deshpande MR, Satyanarayana S, Mannan S, Moonan PK. Evaluation of TB Case Finding through Systematic Contact Investigation, Chhattisgarh, India.external icon Tuberc Res Treat. 2015;2015:670167. doi: 10.1155/2015/670167. Epub 2015 Jul 6. PMID: 26236503.
Kurbatova EV, Cegielski JP, Lienhardt C, Akksilp R, Bayona J, Becerra MC, Caoili J, Contreras C, Dalton T, Danilovits M, Demikhova OV, Ershova J, Gammino VM, Gelmanova I, Heilig CM, Jou R, Kazennyy B, Keshavjee S, Kim HJ, Kliiman K, Kvasnovsky C, Leimane V, Mitnick CD, Quelapio I, Riekstina V, Smith SE, Tupasi T, van der Walt M, Vasilyeva IA, Via LE, Viiklepp P, Volchenkov G, Walker AT, Wolfgang M, Yagui M, Zignol M. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies.external icon Lancet Respir Med. 2015 Mar;3(3):201-9. doi: 10.1016/S2213-2600(15)00036-3. Epub 2015 Feb 26. PMID: 25726085.
Kurbatova EV, Dalton T, Ershova J, Tupasi T, Caoili JC, Van Der Walt M, Kvasnovsky C, Yagui M, Bayona J, Contreras C, Leimane V, Via LE, Kim H, Akksilp S, Kazennyy BY, Volchenkov GV, Jou R, Kliiman K, Demikhova OV, Cegielski JP. Additional drug resistance of multidrug-resistant tuberculosis in patients in 9 countries. Emerg Infect Dis.external icon 2015 Jun;21(6):977-83. doi: 10.3201/eid2106.141329. PMID: 25988299.
Lim JR, Gandhi NR, Mthiyane T, Mlisana K, Moodley J, Jaglal P, Ramdin N, Brust JC, Ismail N, Rustomjee R, Shah NS. Incidence and Geographic Distribution of Extensively Drug-Resistant Tuberculosis in KwaZulu-Natal Province, South Africa.external icon PLoS One. 2015 Jul 6;10(7):e0132076. doi:10.1371/journal.pone.0132076. eCollection 2015. PMID: 26147963.
Lönnroth K, Migliori GB, Abubakar I, D’Ambrosio L, de Vries G, Diel R, Douglas P, Falzon D, Gaudreau MA, Goletti D, González Ochoa ER, LoBue P, Matteelli A, Njoo H, Solovic I, Story A, Tayeb T, van der Werf MJ, Weil D, Zellweger JP, Abdel Aziz M, Al Lawati MR, Aliberti S, Arrazola de Oñate W, Barreira D, Bhatia V, Blasi F, Bloom A, Bruchfeld J, Castelli F, Centis R, Chemtob D, Cirillo DM, Colorado A, Dadu A, Dahle UR, De Paoli L, Dias HM, Duarte R, Fattorini L, Gaga M, Getahun H, Glaziou P, Goguadze L, Del Granado M, Haas W, Järvinen A, Kwon GY, Mosca D, Nahid P, Nishikiori N, Noguer I, O’Donnell J, Pace-Asciak A, Pompa MG, Popescu GG, Robalo Cordeiro C, Rønning K, Ruhwald M, Sculier JP, Simunović A, Smith-Palmer A, Sotgiu G, Sulis G, A Torres-Duque C, Umeki K, Uplekar M, van Weezenbeek C, Vasankari T, Vitillo RJ, Voniatis C, Wanlin M, Raviglione MC. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J.external icon 2015 Apr;45(4):928-52. doi: 10.1183/09031936.00214014.
Maama-Maime LB, Mareka M, Ershova JV, Tlali TE, Kao K, Phalatse M, Polansky L, Beres LK, Letsie M, Holtz TH. Antituberculosis Drug Resistance Survey in Lesotho, 2008-2009: Lessons Learned.external icon PLoS One. 2015 Jul 24;10(7):e0133808. doi: 0.1371/journal.pone.0133808. eCollection 2015. PMID: 26207630.
Mangan JM, Galindo-Gonzalez S, Irani TA. Development and Initial Testing of Messages to Encourage Tuberculosis Testing and Treatment Among Bacille Calmette-Guerin (BCG) Vaccinated Persons. J Immigr Minor Health.external icon 2015 Feb;17(1):79-88. doi: 10.1007/s10903-013-9928-z.
Mase SR, Jereb JA, Gonzalez D, Martin F, Daley CL, Fred D, Loeffler A, Menon L, Morris SB, Brostrom R, Chorba T, Peloquin CA. Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-Resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands.external icon Pediatr Infect Dis J. 2015 Dec 10. [Epub ahead of print]. PMID: 26658531.
McAlister AJ, Driscoll J, Metchock B. DNA sequencing for confirmation of rifampin resistance detected by Cepheid Xpert MTB/RIF assay. J Clin Microbiol.external icon 2015 May;53(5):1752-3. doi: 10.1128/JCM.03433-14. Epub 2015 Mar 4.
*McCarthy KM, Scott LE, Gous N, Tellie M, Venter WD, Stevens WS, Van Rie A.*High incidence of latent tuberculous infection among South African health workers: an urgent call for action.external icon Int J Tuberc Lung Dis.external icon 2015 Jun;19(6):647-53. doi: 10.5588/ijtld.14.0759.
Miller TL, Wilson FA, Pang JW, Beavers S, Hoger S, Sharnprapai S, Pagaoa M, Katz DJ, Weis SE. Mortality hazard and survival after tuberculosis treatment. Am J Public Health.external icon 2015 May;105(5):930-7. doi: 10.2105/AJPH.2014.302431. Epub 2015 Mar 19.
Miramontes R, Hill AN, Yelk Woodruff RS, Lambert LA, Navin TR, Castro KG, LoBue PA. Tuberculosis Infection in the United States: Prevalence Estimates from the National Health and Nutrition Examination Survey, 2011-2012.external icon PLoS One. 2015 Nov 4;10(11):e0140881. doi: 10.1371/journal.pone.0140881. eCollection 2015. PMID: 26536035.
Moore BK, Anyalechi E, van der Walt M, Smith S, Erasmus L, Lancaster J, Morris S, Ndjeka N, Ershova J, Ismail N, Burton D, Menzies H. Epidemiology of drug-resistant tuberculosis among children and adolescents in South Africa, 2005-2010.external icon Int J Tuberc Lung Dis. 2015 Jun;19(6):663-669. doi: 10.5588/ijtld.14.0879. PMID: 25946356.
Mphaphlele M, Dharmadhikari AS, Jensen PA, Rudnick SN, van Reenen TH, Pagano MA, Leuschner W, Sears TA, Milonova SP, van der Walt M, Stoltz AC, Nardell EA. Institutional Tuberculosis Transmission. Controlled Trial of Upper Room Ultraviolet Air Disinfection: A Basis for New Dosing Guidelines. Am J Respir Crit Care Med.external icon 2015 Aug 15;192(4):477-84. doi: 10.1164/rccm.201501-0060OC.
Musau S, McCarthy K, Okumu A, Shinnick T, Wandiga S, Williamson J, Cain K. Experience in implementing a quality management system in a tuberculosis laboratory, Kisumu, Kenya.external icon Int J Tuberc Lung Dis. 2015 Jun;19(6):693-695. doi: 10.5588/ijtld.14.0886.PMID: 25946361.
Nachman S, Ahmed A, Amanullah F, Becerra MC, Botgros R, Brigden G, Browning R, Gardiner E, Hafner R, Hesseling A, How C, Jean-Philippe P, Lessem E, Makhene M, Mbelle N, Marais B, McIlleron H, McNeeley DF, Mendel C, Murray S, Navarro E, Anyalechi EG, Porcalla AR, Powell C, Powell M, Rigaud M, Rouzier V, Samson P, Schaaf HS, Shah S, Starke J, Swaminathan S, Wobudeya E, Worrell C. Towards early inclusion of children in tuberculosis drugs trials: a consensus statement. Lancet Infect Dis.external icon 2015 Jun;15(6):711-20. doi: 10.1016/S1473-3099(15)00007-9. Epub 2015 May 6. PMID: 25957923.
Nicol MP, Gnanashanmugam D, Browning R, Click ES, Cuevas LE, Detjen A, Graham SM, Levin M, Makhene M, Nahid P, Perez-Velez CM, Reither K, Song R, Spiegel HM, Worrell C, Zar HJ, Walzl G. A Blueprint to Address Research Gaps in the Development of Biomarkers for Pediatric Tuberculosis.external icon Clin Infect Dis. 2015 Oct 15;61(suppl 3):S164-S172. PMID: 26409279.
Niehaus AJ, Mlisana K, Gandhi NR, Mathema B, Brust JC. High Prevalence of inhA Promoter Mutations among Patients with Drug-Resistant Tuberculosis in KwaZulu-Natal, South Africa. PLoS One.external icon 2015 Sep 2;10(9):e0135003. doi: 10.1371/journal.pone.0135003.
Pagaoa MA, Royce RA, Chen MP, Golub JE, Davidow AL, Hirsch-Moverman Y, Marks SM, Teeter LD, Thickstun PM, Katz DJ; Tuberculosis Epidemiologic Studies Consortium.
Risk factors for transmission of tuberculosis among United States-born African Americans and Whites.external icon Int J Tuberc Lung Dis. 2015 Dec;19(12):1485-92. doi: 10.5588/ijtld.14.0965. PMID:26614190.
Pavlicek RL, Fine-Coulson K, Gupta T, Quinn FD, Posey JE, Willby M, Castro-Garza J, Karls RK. Rv3351c, a Mycobacterium tuberculosis gene that affects bacterial growth and alveolar epithelial cell viability.external icon Can J Microbiol. 2015 Oct 22:1-10. [Epub ahead of print]. PMID: 26492080.
Podewils LJ, Bantubani N, Bristow C, Bronner LE, Peters A, Pym A, Mametja LD. Completeness and Reliability of the Republic of South Africa National Tuberculosis (TB) Surveillance System.external icon BMC Public Health. 2015 Aug 11;15(1):765. doi: 10.1186/s12889-015-2117-3. PMID: 26259599.
Royce RA, Colson PW, Woodsong C, Swinson-Evans T, Walton W, Maiuri A, DeLuca N; Tuberculosis Epidemiologic Studies Consortium (TBESC). Tuberculosis Knowledge, Awareness, and Stigma Among African-Americans in Three Southeastern Counties in the USA: a Qualitative Study of Community Perspectives.external icon J Racial Ethn Health Disparities. 2015 Dec 29. [Epub ahead of print]. PMID: 26715219.
Rutanga C, Lowrance DW, Oeltmann JE, Mutembayire G, Willis M, Uwizeye CB, Hinda R, Bassirou C, Gutreuter S, Gasana M. Latent Tuberculosis Infection and Associated Factors among Health Care Workers in Kigali, Rwanda. PLoS One.external icon 2015 Apr 28;10(4):e0124485. doi: 10.1371/journal.pone.0124485. eCollection 2015.
*Salamon H, Yamaguchi KD, Cirillo DM, Miotto P, Schito M, Posey J, Starks AM, Niemann S, Alland D, Hanna D, Aviles E, Perkins MD, Dolinger DL.*Integration of Published Information Into a Resistance-Associated Mutation Database for Mycobacterium tuberculosis.
J Infect Dis.external icon 2015 Apr 1;211(suppl 2):S50-S57. doi: 10.1093/infdis/jiu816. PMID: 25765106.
Samandari T, Agizew TB, Nyirenda S, Tedla Z, Sibanda T, Mosimaneotsile B, Motsamai OI, Shang N, Rose CE, Shepherd J. Tuberculosis incidence after 36 months’ isoniazid prophylaxis in HIV-infected adults in Botswana: a posttrial observational analysis.external icon AIDS. 2015 Jan 28;29(3):351-9. doi: 10.1097/QAD.0000000000000535. PMID: 25686683.
Scott JC, Shah N, Porco T, Flood J. Cost Resulting from Anti-Tuberculosis Drug Shortages in the United States: A Hypothetical Cohort Study. PLoS One.external icon 2015 Aug 18;10(8):e0134597. doi: 10.1371/journal.pone.0134597. eCollection 2015.
Scott JC, Shah N, Porco T, Flood J. Correction: Cost Resulting from Anti-Tuberculosis Drug
Shortages in the United States: A Hypothetical Cohort Study. PLoS One.external icon 2015 Sep 2;10(9):e0137812. doi: 10.1371/journal.pone.0137812. eCollection 2015. PMID: 26332531.
Shak EB, France AM, Cowan L, Starks AM, Grant J. Representativeness of Tuberculosis Genotyping Surveillance in the United States, 2009-2010. Public Health Rep.external icon 2015 Nov-Dec;130(6):596-601. PMID: 26556930.
Sharma A, Musau S, Heilig CM, Okumu AO, Opiyo EO, Basiye FL, Miruka FO, Kioko JK, Sitienei JK, Cain KP. Assessing the effect of decentralisation of laboratory diagnosis for drug-resistant tuberculosis in Kenya.external icon Int J Tuberc Lung Dis. 2015 Nov;19(11):1348-53. doi: 10.5588/ijtld.15.0328. PMID: 26467587.
Sharma A, Ndisha M, Ngari F, Kipruto H, Cain KP, Sitienei J, Bloss E. A review of data quality of an electronic tuberculosis surveillance system for case-based reporting in Kenya.external icon Eur J Public Health. 2015 May 25. pii: ckv092. [Epub ahead of print]. PMID: 26009610.
Smith SE, Ershova J, Vlasova N, Nikishova E, Tarasova I, Eliseev P, Maryandyshev AO, Shemyakin IG, Kurbatova E, Cegielski JP. Risk factors for acquisition of drug resistance during multidrug-resistant tuberculosis treatment, Arkhangelsk Oblast, Russia, 2005-2010. Emerg Infect Dis.external icon 2015 Jun;21(6):1002-11. doi: 10.3201/eid2106.141907. PMID: 25988954.
Smith T, Samandari T, Abimbola T, Marston B, Sangrujee N. Implementation and Operational Research: Cost-Effectiveness of Antiretroviral Therapy and Isoniazid Prophylaxis to Reduce Tuberculosis and Death in People Living With HIV in Bostwana. J Acquir Immune Defic Syndr.external icon 2015 Nov 1;70(3):e84-93. doi: 10.1097/QAI.0000000000000783.
Starks AM, Avilés E, Cirillo DM, Denkinger CM, Dolinger DL, Emerson C, Gallarda J, Hanna D, Kim PS, Liwski R, Miotto P, Schito M, Zignol M. Collaborative Effort for a Centralized Worldwide Tuberculosis Relational Sequencing Data Platform. Clin Infect Dis.external icon 2015 Oct 15;61Suppl 3:S141-6. doi: 10.1093/cid/civ610.
Sterling TR, Moro RN, Borisov AS, Phillips E, Shepherd G, Adkinson NF, Weis S, Ho C, Villarino MD, Tuberculosis Trials Consortium. Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT TB study. Clin Infect Dis.external icon 2015 Aug 15;61(4):527-35. doi: 10.1093/cid/civ323. Epub 2015 Apr 22.
Trinh TT, Han DT, Bloss E, Le TH, Vu TT, Mai AH, Nguyen NV, Nguyen LT, Dinh SN, Whitehead S. **I**mplementation and evaluation of an isoniazid preventive therapy pilot program among HIV-infected patients in Vietnam, 2008-2010.external icon Trans R Soc Trop Med Hyg. 2015 Oct;109(10):653-9. doi: 10.1093/trstmh/trv074. PMID: 26385936.
Tryon C, Hopkins P, Khan A, Walton W. Teachback methodology: building global training capacity with a unique training-of-trainers course.external icon Public Health Action. 2015 Mar 21;5(1):79-82. doi: 10.5588/pha.14.0103. PMID: 26400606.
Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B, Nachman S, Oliveira R, Moro RN, Shang N, Goldberg SV, Sterling TR for the International Maternal Pediatric and Adolescents AIDS Clinical Trials Group (IMPAACT) and the Tuberculosis Trials Consortium (TBTC). Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA Pediatr.external icon 2015 Mar;169(3):247-55. doi: 10.1001/jamapediatrics.2014.3158.
*Viney K, Cavanaugh J, Kienene T, Harley D, Kelly PM, Sleigh A, O’Connor J, Mase S.***Tuberculosis** and diabetes mellitus in the Republic of Kiribati: a case-control study*.*external icon Trop Med Int Health.external icon 2015 May;20(5):650-657. doi: 10.1111/tmi.12462. Epub 2015 Feb 26.
Volkmann T, Moonan PK, Miramontes R, Oeltmann JE. Tuberculosis and excess alcohol use in the United States, 1997-2012. Int J Tuberc Lung Dis.external icon 2015 Jan;19(1):111-9. doi:10.5588/ijtld.14.0516.
Whitfield MG, Warren RM, Streicher EM, Sampson SL, Sirgel FA, van Helden PD, Mercante A, Willby M, Hughes K, Birkness K, Morlock G, van Rie A, Posey JE. Mycobacterium tuberculosis pncA Polymorphisms That Do Not Confer Pyrazinamide Resistance at a Breakpoint Concentration of 100 Micrograms per Milliliter in MGIT. J Clin Microbiol.external icon 2015 Nov;53(11):3633-5. doi: 10.1128/JCM.01001-15. Epub 2015 Aug 19. PMID: 26292310.
Willby M, Sikes RD, Malik S, Metchock B, Posey JE. Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother.external icon 2015 Sep;59(9):5427-34. doi: 10.1128/AAC.00662-15. Epub 2015 Jun 22.
Yakrus MA, Metchock B, Starks AM. Evaluation of a u.s. Public health laboratory service for the molecular detection of drug resistant tuberculosis.external icon Tuberc Res Treat. 2015;2015:701786. doi: 10.1155/2015/701786. Epub 2015 Feb 22. PMID: 25793126.je
Yelk Woodruff RS, Pratt, RH, Armstrong, LR. The US National Tuberculosis Surveillance System: A Descriptive Assessment of the Completeness and Consistency of Data Reported from 2008 to 2012external icon. JMIR Public Health Surveill 2015 (Oct 15); 1(2):e15. doi:10.2196/publichealth.4991.
Yeole, RD, Khillare K, Chadha VK, Lo T, Kumar AM. Tuberculosis case notification by private practitioners in Pune, India: how well are we doing? Public Health Action.external icon 2015 Sep 21;5(3):173-9. doi: 10.5588/pha.15.0031.
Yuen CM, Krapivina TM, Kazennyy BY, Kiryanova EV, Aksenova VA, Gordina A, Finlay AM, Cegielski JP. Annual risk of tuberculous infection measured using serial skin testing, Orel Oblast, Russia, 1991-2005. Int J Tuberc Lung Dis.external icon 2015 Jan;19(1):39-43. doi: 10.5588/ijtld.14.0445. PMID: 25519788.
Yuen CM, Kurbatova EV, Tupasi T, Caoili JC, Van Der Walt M, Kvasnovsky C, Yagui M, Bayona J, Contreras C, Leimane V, Ershova J, Via LE, Kim H, Akksilp S, Kazennyy BY, Volchenkov GV, Jou R, Kliiman K, Demikhova OV, Vasilyeva IA, Dalton T, Cegielski JP. Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study.external icon PLoS Med. 2015 Dec 29;12(12):e1001932. doi: 10.1371/journal.pmed.1001932. eCollection 2015 Dec. PMID: 26714320.
							
					
						Page last reviewed:  November 4, 2015					Content source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention homeTuberculosis
Basic TB Factsplus icon
How TB Spreads
Latent TB Infection and TB Disease
Signs & Symptoms
TB Risk Factors
Exposure to TB
TB Prevention
Vaccines
TB & HIV Coinfection
TB and Diabetes
TB Terms
Personal Storiesplus icon
Stories by Topic
Archived Stories
Testing & Diagnosisplus icon
Who Should be Tested
Testing for TB Infection
Testing in BCG-Vaccinated Persons
TB Screening and Testing of Health Care Personnel
Testing During Pregnancy
Diagnosing latent TB infection and TB disease
Treatmentplus icon
Deciding When to Treat Latent TB Infection
Treatment Regimens for Latent TB Infection (LTBI)
Treatment for TB Disease
Adverse Events
TB Treatment of Persons Living with HIV
TB Treatment and Pregnancy
TB Treatment for Children
Drug-Resistant TB
Researchplus icon
TB Epidemiologic Studies Consortiumplus icon
Research Projects
Publications
TB Trials Consortiumplus icon
Study Descriptions
Background
Behavioral & Social Science Research
Health Care Settingsplus icon
TB Infection Control in Health Care Settings
Resources for TB Screening and Testing of Health Care Personnelplus icon
Frequently Asked Questions
TB in Specific Populationsplus icon
Health Disparities
Asian Persons
Black or African American Persons
Hispanic or Latino Persons
Children
Pregnancy
Correctional Facilities
People Experiencing Homelessness
International Travelers
Laboratory Informationplus icon
Drug Susceptibility Testing
False-Positive Investigation Toolkit
Interim Laboratory Biosafety Guidance for XDR *Mycobacterium* tuberculosis strains
Model Performance Evaluation Program (MPEP)
Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus icon
Executive Summary
Introduction
Background on Tests for Molecular Detection of DR
General Considerations and Principles for a Molecular DR Testing Service
Possible Scenarios and Scope of Testing for a Molecular DR Testing Service
Research Needs
General Recommendations of the Expert Panel
Communication Plan for the Report
Recommendations
References
Panel Members and CDC Participants
Appendix 1
Appendix 2
Appendix 3
The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus icon
General Considerations
General Recommendations of the Expert Panel
Recommendations to ACET, CDC, DTBE
Data & Statisticsplus icon
TB Incidence in the United States
Reported TB in the US, 2019 Surveillance Report
Trends in Tuberculosis 2019
Tuberculosis in the United States, 2019 (Slide Set)
Archived Surveillance Reports and Slide Sets
2019 State and City Report
Archived State and City Reports
Professional Resources & Toolsplus icon
Tools for Healthcare Providersplus icon
Interactive Core Curriculum on Tuberculosis: What the Clinician Should Know
Resources for TB Programsplus icon
Notice of Funding Opportunity (NOFO)
Program Evaluation
TB Centers of Excellence
TB Community Engagement Network
Publications & Productsplus icon
Patient and Public Materials
Fact Sheetsplus icon
General
Data & Statistics
Drug-Resistant TB
Infection Control & Prevention
TB in Specific Populations
Treatment
Testing & Diagnosis
Vaccines & Immunizations
Guidelinesplus icon
Control & Elimination
Drug-Resistant TB
Infection Control & Prevention
Laboratory & Genotyping
TB & HIV
TB in Specific Populations
Testing & Diagnosis
Treatment
Vaccines & Immunizations
Archived TB Guidelines
Guides & Toolkitsplus icon
Aggregate Reports
CDC TB Surveillance Training
Core Curriculum
Effective TB Interviewing for Contact Investigation
Ethnographic Guides
False-Positive Investigation Toolkit
Forging Partnerships to Eliminate TB
Guide to Application of Genotyping
LTBI: A Guide for Primary Health Care Providers
Mantoux Tuberculin Skin Testing Products
Report of Verified Case of Tuberculosis (RVCT)
Self-Study Modules
TB Contact Investigation Interviewing Skills Course
TB eDOT Toolkit
Understanding the TB Cohort Review Process
Newslettersplus icon
TB Notes, No. 1, 2021
TB Notes, No. 4, 2020
TB Notes, No. 3, 2020
TB Notes, No. 2, 2020
TB Notes, No. 1, 2020
TB Notes, No. 4, 2019
TB Notes, No. 3, 2019
TB Notes, No. 2, 2019
TB Notes, No. 1, 2019
TB Notes, No. 6, 2018
TB Notes, No. 5, 2018
TB Notes, No. 4, 2018
TB Notes, No. 3, 2018
TB Notes, No. 2, 2018
TB Notes, No. 1, 2018
TB Notes, No. 5, 2017
TB Notes, No. 4, 2017
TB Notes, No. 3, 2017
TB Notes, No. 2, 2017
TB Notes, No. 1, 2017
TB Notes, No. 5, 2016
TB Notes, No. 4, 2016
TB Notes, No. 3, 2016
TB Notes, No. 2, 2016
TB Notes, No. 1, 2016
Pamphlets, Brochures, Bookletsplus icon
Questions and Answers
Patient Education Series
Tuberculosis – Get the Facts
Tuberculosis – The Connection between TB and HIV
12-Dose Regimen for Latent TB Infection-Patient Education Brochure
Postersplus icon
Mantoux Tuberculin Skin Test Wall Chart
World TB Day
Think TB
Stop TB
Take on TB
Reports & Articlesplus icon
DTBE Authored Journal Articles
Tuberculosis Laboratory Aggregate Reports
Slide Setsplus icon
Introduction to Tuberculosis
Epidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016
Self-Study Modules on Tuberculosis, 1-5 Slide Sets
The Tuberculosis (TB) in Correctional Settingsplus icon
Facilitator Guide
Introduction to TB Genotyping
Epidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017
Prevention and Control of Tuberculosis in Correctional and Detention Facilities
Guidelines for Preventing the Transmission of M. TB in Health care Settings
Investigation of Contacts of Persons with Infectious TB
Epidemiology of Pediatric Tuberculosis in the United States
Targeted Tuberculosis Testing and Treatment of Latent Tuberculosis Infection
Electronic Tools & Resources
Web-Based Courses & Webinarsplus icon
TB 101 for Health Care Workersplus icon
TB 101
Interactive Core Curriculum
Content Syndication
Infographicsplus icon
Social Media Graphics
Customizable Take on TB Infographic with Instructions
Events
World TB Dayplus icon
Resources
U.S. TB Championsplus icon
2021 CDC U.S. TB Elimination Champions
2020 CDC U.S. TB Elimination Champions
2019 CDC U.S. TB Elimination Champions
2018 CDC U.S. TB Elimination Champions
2017 CDC U.S. TB Elimination Champions
2016 CDC U.S. TB Elimination Champions
News & Events
History
Featuresplus icon
TB Risk Factors
Treating Latent TB Infection with Short-Course Regimens
World Tuberculosis (TB) Day 2021
World Tuberculosis (TB) Day 2020
Linksplus icon
State TB Control Offices
About Usplus icon
Mission Statement and Activitiesplus icon
DTBE Strategic Plan
National TB Program Objectives
Organization Chart
Advisory Groupsplus icon
Federal TB Task Force


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue